BioSpace News Archive

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”), today announced that the Company is partnering with the American Liver Foundation (ALF) in an educational campaign about chronic liver cirrhosis and its complications and to raise awareness among potential patients and healthcare providers about the Company’s Phase 2b Study of BIV201 (continuous infusion terlipressin).

Global Blood Therapeutics, Inc. announced that on December 1, 2021, the compensation committee of GBT’s board of directors granted 24 new employees restricted stock units for an aggregate of 80,270 shares of the company’s common stock.

HTG Molecular Diagnostics, Inc., a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that it has exceeded $1 million of revenue recognized from sales of its HTG Transcriptome Panel as of November 30, 2021.

Aprea Therapeutics, Inc. (Nasdaq: APRE), today announced that the U.S. Food and Drug Administration (FDA) has removed the full clinical hold on the Company’s clinical trial evaluating the combination of its lead compound, eprenetapopt, with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies.

Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of its neutralizing antibody candidate, ABP 310’s ability to neutralize the emerging SARS-CoV-2 Omicron variant.

BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), is pleased to announce it has obtained the first set of positive data showing anti-depressant properties of its lead compound, 2-bromo-LSD (“TD-0148A”) in animal depression models, as part of its collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton University’s (Carleton) Department of Neuroscience.

XORTX Therapeutics Inc., a pharmaceutical therapeutics company focused on developing innovative therapies to treat progressive kidney disease, announced that James Molloy, Senior Biotechnology Analyst at A.G.P./Alliance Global Partners, has initiated research coverage on XORTX.

I-Mab (the “Company”) (Nasdaq: IMAB), today announced that it will hold a call with investors at 8:00 a.m. EST on December 14 to provide an in-depth analysis of the most recent clinical data from an ongoing clinical trial of lemzoparlimab in combination with rituximab in relapsed or refractory non-Hodgkins’s lymphoma.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that it has entered into a clinical collaboration with Clover Biopharmaceuticals, Ltd.

Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced bullish expectations for prescription and net revenue growth in the fourth quarter of 2021.